Journal of International Oncology

Journal of International Oncology››2019,Vol. 46››Issue (6): 374-377.doi:10.3760/cma.j.issn.1673-422X.2019.06.013

Previous ArticlesNext Articles

Application of metronomic chemotherapy in the treatment of advanced nonsmall cell lung cancer

Zhu Qingqing1,2, Xie Chao2, Song Bao3, Zhang Qiujing1,2, Liu Jie2

  1. 1School of Medicine and Life Sciences, University of JinanShandong Academy of Medical Sciences, Jinan 250022, China; 2Department of Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan 250117, China; 3Basic Laboratory, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan 250117, China
  • Online:2019-06-08Published:2019-07-11
  • Contact:Liu Jie, Email: lj691012@126.com E-mail:lj691012@126.com

PDF

612

Abstract:Metronomic chemotherapy is a brandnew and multitarget chemotherapy strategy. Totally different from the traditional chemotherapy, metronomic chemotherapy can exert synergistic and durable antitumor effects via multiple mechanisms, including cytotoxic effect, antiangiogenesis, immune regulation and so on. Single and combined therapy modes of metronomic oral vinorelbine have good curative effects and safeties for the treatment of advanced nonsmall cell lung cancer. With the indepth understanding of metronomic chemotherapy, it will certainly become an important treatment mode for advanced nonsmall cell lung cancer.

Key words:Carcinoma, non-small-cell lung,Chemoradiotherapy,Drug therapy, combination,Metronomic chemotherapy,Vinorelbine